The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
I have the RTO date of 14 June 2017 in my eDiary. I probably got this date during my research in the past, but unfortunately I cannot verify the source of my information even though I checked some RNS's and CAF website.
It is £1 million (I checked RNS)
.....just to add to my previous post, that the SP stands a v good chance to increase on any good news (or rumours!)
My concern with your view on this, is that it would dilute the SP. However, I suspect you are correct. I had a look at the latest Financial Report (only could find the period ending 30 June 2016) and then it showed cash reserves at US$0.2m, probably not enough for the change of name (CAF to PERE) and RTO.......
HermanusInclusus, I don't know where you get the 400K shares from. Grant Stevens 3.64% equates to 2,982,018 shares according to the RNS.
.....just annoying we have seen a drop again today, but I think this is the nature of this share. At anytime it can go very high again with some good news. We as LTH just need to be patient. The long term will be positive. I see dips as an opportunity to top up. Best wishes to all LTH.
There is an error in the calculations entered by golddust88, the actual figures are much better. The potential value is £5.55 per share (not £4.60). The error is - I quote "CSD500 @10% market share of a $6billion pa market is $600 million=£450 million @ 5% royalty rate is £9 million per annum " End of Quote. 5% of £450million is £22.5 million NOT £9 million. So, if we were to mirror all calculations again that makes the potential £5.55 per share. Old calculations £69m x p/e 8 = £552m New Calculations £82.5m x p/e 8 = £660m £552m : £63m (Co Value) = 8.76 times current sp £660 : £63m = 10.47 8.76 x .53 (Current sp) = £4.64 10.47 x .53 = £5.55 The potential is massive and in my opinion we shall see bursts of sp increases as stated by golddust88.
Hawkhead, if FUM is such a bad investment and a waste of your time and money, why are you posting here. Stop de-ramping and please go elsewhere. Nobody is asking to comment here. You made your views known, so please move on. Thanks and Goodbye.
h45ky, Thanks for sharing this link, really excellent news on the progress being made and FUM's planning into other markets such as US, UK and Europe. Definitely worth a watch. Disappointingly the sp went down, but I do find that FUM compared to other shares I hold, tends to move very quickly upwards, so I am holding long term. There is a sizeable market for the type of innovative products designed/developed by FUM, so there is a massive potential.
I will be in Portugal in June/July, so I will check if CSD500 under Blue Diamond is for sale there. I will not use it because I don't need it 8-) FUM will do extremely well, just will take a little time. Buy on dips. I reckon this product will give some stiff opposition to the likes of Pfizer, Glaxo..........LOL
Just for information....... at the end of these 2 RNS's there is a paragraph that states "Shareholders should note that this transaction does not constitute a reverse takeover under the AIM Rules"
I have list here a Summary of FUM Products to the best of my knowledge. Please let me know if you sure there is something incorrect. Sexual Health Products: CSD500 Commercial manufacture of product launch of CSD500 in Saudi Arabia, where regulatory approval has already been granted. When I was reading the CSD500 Review dated 23 June 2016, all references to EU launch indicates it is imminent in 2017 because of comments made like "Durex’s customer care adviser said it'd be available soon into the New Year" (2017) and "accessible as early as next year" (2017). I noticed this product is available in Belgium and Netherlands, I wonder what the users say about the product and what sales are in these two countries ! MED2002 FUM's gel for treatment of ED erectile dysfunction to be sold OTC in the future. Potential market 1.6B$. Final Phase III programme underway. Pain relief Products: TPR100 Topical diclofenac pain relief gel. First Licensing agreement signed. Further discussions under way. Currently in last Phase III development. TPR100 (I think but not sure) will be distributed by STADA marketed in the UK, but nowhere else to start with. TIB200 Topical ibuprofen pain relief gel. Out licensing discussions underway. Currently in mid Phase III development. SPR300 Topic methyl salicylate pain relief gel. Possible follow on product TPR100/TIB200.
You are probably right and I hope you are. FUM does tend to jump in 20's LOL.................. I note the FUM 2016 results on Thu 23 March - what is your view, are the results sales, revenue, or the results in medicine development, licenses ?
I am an investor not a trader. I believe in FUM. Several pennies will make several thousands if we believe the long term return - It all depends how much one is investing. It has worked for me before and will work again. It's my strategy.
levistubbs, thanks for the info. Do you know approx. when these investments were made under PJ ? Just trying to gauge how much more movement is there on the SP going forward.......... (I am planning a top up! )
I note CAF Investments as follows: (I have a question at the end) RNS 2789W 9 Feb 2017 Investment Agreement - signed an Investment Agreement with US Lithium (Pty) Ltd ("USL"), a private Australian company, to acquire up to a 47.5% shareholding in USL. USL has interests in lithium exploration licences in Arizona and New Mexico. RNS 6514V 1 Feb 2017 Investment Agreement Botswana - CAF signed an Investment Agreement with Global Exploration Technologies (Pty) Ltd ("GET"), a private Australian company, to acquire a 48.88% shareholding in GET who has five exploration licences in the Kalahari Copper Belt in Botswana held through three Botswanan subsidiary companies. I am relatively new to CAF investment, so does anyone know if these investments are new, as per recent RNS's ? Or thy have been around for sometime but the RNS's happen to just make mention of them ?